Fiche publication
Date publication
janvier 2017
Journal
Archives of cardiovascular diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MONASSIER Laurent
Tous les auteurs :
Ayme-Dietrich E, Aubertin-Kirch G, Maroteaux L, Monassier L
Lien Pubmed
Résumé
Plasma 5-hydroxytryptamine (5-HT; serotonin), released from blood platelets, plays a major role in the human cardiovascular system. Besides the effect of endogenous serotonin, many drugs targeting serotonergic receptors are widely used in the general population (antiobesity agents, antidepressants, antipsychotics, antimigraine agents), and may enhance the cardiovascular risk. Depending on the type of serotonin receptor activated and its location, the use of these compounds triggers acute and chronic effects. The acute cardiovascular response to 5-HT, named the Bezold-Jarish reflex, leads to intense bradycardia associated with atrioventricular block, and involves 5-HT, 5-HT, 5-HT and 5-HT receptors. The chronic contribution of 5-HT and its receptors (5-HT and 5-HT) in cardiovascular tissue remodeling, with a particular emphasis on cardiac hypertrophy, fibrosis and valve degeneration, will be explored in this review. Finally, through the analysis of the effects of sarpogrelate, some new aspects of 5-HT receptor pharmacology in vasomotor tone regulation and the interaction between endothelial and smooth muscle cells will also be discussed. The aim of this review is to emphasize the cardiac side effects caused by serotonin receptor activation, and to highlight their possible prevention by the development of new drugs targeting this system.
Mots clés
Cardiac hypertrophy, Cardiac remodeling, Dégénérescence valvulaire, Fibrose, Fibrosis, Hypertrophie cardiaque, Remodelage cardiaque, Serotonin, Sérotonine, Valve degeneration
Référence
Arch Cardiovasc Dis. 2017 01;110(1):51-59
